Antiviral activity of Bifidobacterium adolescentis SPM1605 against Coxsackievirus B3

Biotechnol Biotechnol Equip. 2014 Jul 4;28(4):681-688. doi: 10.1080/13102818.2014.945237. Epub 2014 Oct 20.

Abstract

Bifidobacteria are considered one of the most beneficial probiotics and have been widely studied for their effects against specific pathogens. The present study investigated the antiviral activity of probiotics isolated from Koreans against Coxsackievirus B3 (CVB3). The effect of probiotic isolates against CVB3 was measured by the plaque assay and cellular toxicity of bifidobacteria in HeLa cells was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Among 13 probiotic isolates, 3 Bifidobacterium adolescentis, 2 Bifidobacterium longum and 1 Bifidobacterium pseudocatenulatum had an antiviral effect against CVB3, while the others did not show such effect. B. adolescentis SPM1605 showed the greatest inhibitory properties against CVB3. When the threshold cycle (CT) values for the treated B. adolescentis SPM1605 samples were compared to the results for the non-treated samples, it was shown that the amplified viral sequences from the CVB3 had their copy number lowered by B. adolescentis SPM1605. Moreover, the gene expression in infected HeLa cells was also inhibited by 50%. The results suggest that B. adolescentis SPM1605 suppresses CVB3 and could be used as an alternative therapy against infectious diseases caused by coxsackieviruses.

Keywords: Bifidobacterium adolescentis; Coxsackievirus; HeLa cells; plaque reduction assay; real-time qPCR.

Publication types

  • Review

Grants and funding

This work was supported by Business for Cooperative R&D between Industry, Academy, and Research Institute funded by the Korea Small and Medium Business Administration [grant number 000449270111].